VIP (1-12)
HSDAVFTDNYTR-acid
Description
Application Data
Description
-
Vasoactive intestinal peptide (VIP) is a neuropeptide involved in neurotransmission and smooth muscle relaxation. VIP (1-12) is used as a standard in mass spectrometry (MS).
Application Data
-
Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb1001126 Molecular Weight 1424.6 Sequence (one letter code) HSDAVFTDNYTR-acid
Sequence (three letter code) H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-OH
Purity >95% cas 120928-03-2 Storage -20°C References Gonzalez-Rey et al., (2006). The therapeutic effect of the vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am. J. Clin. Pathol., 168(4): 1179. doi: 10.2353/ajpath.2006.051081.
Shin et al., (2011). Peptide C-terminal sequence analysis by MALDI-TOF MS utilising EDC coupling with Br signature. Bull Korean Chem Soc, 32(4): 1183. doi: 10.5012/bkcs.2011.32.4.1183.
Zhang et al., (2007). Site-specific pyrolysis-induced cleavage at aspartic acid residue in peptides and proteins. J. Proteome Res., 6(5): 1700. doi: 10.1021/pr060648w.
Manufactured in: United Kingdom Vasoactive intestinal peptide (VIP) is a neuropeptide found throughout the body and the central nervous system (CNS). VIP is located within cell bodies and nerve endings of the enteric nervous system, brain and pancreas. VIP neurons in the peripheral system fire to regulate blood vessels, and the CNS innervate cerebral vasculature. VIP binds to G protein-coupled receptors VPAC1 and VPAC2. VIP and VPAC2 are detected in circular smooth muscle cells of cerebral arterioles. VIP and VPAC1 are also found in lymphatic tissue. VIP can block inflammation, modify the Th response favouring Th2 and induce regulatory T cells. VIP has been recognised as an immunosuppressive neuropeptide and studied as a treatment for inflammatory conditions. Model administration of VIP and VIP (1-12) can reduce the severity of experimental autoimmune encephalomyelitis (EAE). This suggests VIP and fragment (1-12) could lead to VIP-based therapies for inflammatory disorders such as multiple sclerosis (MS).
The VIP N-terminal (1-12) has also been used in mass spectrometry as a control and to generate a method for C-terminal sequence analysis by MALDI-TOF MS.